Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $846000.0.

  • Anika Therapeutics' Net Income towards Common Stockholders rose 10301.36% to $846000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 5650.33%. This contributed to the annual value of -$47.6 million for FY2024, which is 3997.45% up from last year.
  • Per Anika Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $846000.0 for Q3 2025, which was up 10301.36% from $677000.0 recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Net Income towards Common Stockholders peaked at $16.2 million during Q4 2023, and registered a low of -$28.1 million during Q3 2024.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$2.6 million (2024), whereas its average is -$2.3 million.
  • Data for Anika Therapeutics' Net Income towards Common Stockholders shows a peak YoY increase of 41137.91% (in 2022) and a maximum YoY decrease of 85398.55% (in 2022) over the last 5 years.
  • Over the past 5 years, Anika Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$3.2 million in 2021, then soared by 411.38% to $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then crashed by 219.74% to -$19.4 million in 2024, then soared by 104.37% to $846000.0 in 2025.
  • Its Net Income towards Common Stockholders stands at $846000.0 for Q3 2025, versus $677000.0 for Q2 2025 and -$915000.0 for Q1 2025.